Drug Trial Radar · NCT07914062
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Feb 2027
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Antev Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 19 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PRECISION-E2 is a Phase IIa randomized, placebo-controlled study evaluating the pharmacodynamic profile, safety and tolerability of teverelix in premenopausal women with moderate-to-severe pain associated with endometriosis in the United Arab Emirates. The study will characterize the magnitude and duration of estradiol suppression following a single administration of teverelix and evaluate dose and route of administration, including subcutaneous and intramuscular administration, to inform subsequent clinical development. The study also incorporates a prospective precision medicine component designed to explore associations between genomic variation and pharmacodynamic and clinical response to teverelix. In participants enrolled in the Emirati Genome Program, genomic data will be integrated with hormonal, pharmacokinetic and clinical outcomes to investigate potential biological determinants of treatment response.
Conditions
- Endometriosis Pelvic
- Endometriosis Ovaries
- Premenopausal
- Endometriosis (Diagnosis)
- Dysmenorrhoea
- Dyspareunia (Female)
Interventions
Teverelix DPDrug
Single dose at Day 1 of 60 mg injection SC
Teverelix DPDrug
Single dose at Day 1 of 90 mg injection SC.
Teverelix DPDrug
Single dose at Day 1 of 90 mg injection IM
Teverelix DP PlaceboDrug
Single dose at Day 1 of placebo injection SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Serum Estradiol Maintained Within 20-50 pg/mL for at Least 14 Consecutive DaysTime frame: From Day 1 to Day 197
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.